Form 10-Q · Quarterly report
Zoetis 10-Q, filed Aug 6, 2026
- Filed
- CIK
- 0001555280
- Accession no.
- 0001555280-26-000040
Summary
Zoetis reported second-quarter 2026 revenue of $2.47 billion, essentially flat versus the prior-year period, with net income attributable to Zoetis down 5% to $691 million and adjusted net income down 1% to $781 million. For the six months ended June 30, 2026, revenue rose 1% to $4.73 billion while net income fell 3% to $1.29 billion, and the animal-health company flagged tariffs, trade protection measures, disease outbreaks, and foreign-exchange moves as factors affecting results.
Key points
- Second-quarter 2026 operational revenue fell 2% and operational net income fell 6%, excluding foreign exchange
- Six-month 2026 adjusted net income was $1.43 billion, roughly flat year over year
- About 46% of first-half 2026 revenue was denominated in foreign currencies, and foreign exchange added roughly 2 percentage points to year-over-year revenue growth
- Zoetis sells about 300 product lines in more than 100 countries, organized into U.S. and International segments
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Overview of our business Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.